Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine

Behavioural Brain Research

Volumn 223, Issue 1, 2011, Pages 227-232

  Bhatia, Kamal S ^a   Szabo, Steven T ^a   Fowler, J Corey ^a   Wetsel, William C ^a   Lee, Tong H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ketanserin; Methamphetamine sensitization reversal; Mirtazapine; Ondansetron; Pergolide; Psychostimulant abuse

Indexed keywords

KETANSERIN; METHAMPHETAMINE; MIRTAZAPINE; ONDANSETRON; PERGOLIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SENSITIZATION; DRUG WITHDRAWAL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; INFUSION PUMPS, IMPLANTABLE; KETANSERIN; MALE; METHAMPHETAMINE; MIANSERIN; ONDANSETRON; PERGOLIDE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79957975599     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.04.045     Document Type: Article

References (51)

1. Substance Abuse and Mental Health Services Administration Results from the 2008 national survey on drug use and health: national findings 2009, Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434, Rockville, MD.
2. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Treatment episode data set (TEDS): 1996-2006 2008, National Admissions to Substance Abuse Treatment Services, DASIS Series: S-43, DHHS Publication No. SMA 08-4347, Rockville, MD.
3. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Drug abuse warning network, 2007 2010, National estimates of drug-related emergency department visits, Rockville, MD.
4. Huddleston C.W., Marlowe D.B., Casebolt R. Painting the current picture: a national report card on drug courts and other problem-solving court programs in the United States 2008, National Drug Court Institute, Washington, DC.
5. Vocci F.J., Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005, 18:265-270.
6. Acri J.B., Chiang C.N., McCann D.J., Shih M.L., Vocci F.J. Summary of NIDA medications workshop: new opportunities for chemists and pharmacologists. Drug Alcohol Depend 2008, 92:307-311.
7. Zhang X., Lazarus C., Wetsel W.C., Davidson C., Lee T.H., Ellinwood E.H. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. Neuropsychopharmacology 2007, 32:377-387.
8. Davidson C., Lazarus C., Xiong X., Lee T.H., Ellinwood E.H. 5-HT2 antagonists given in the acute withdrawal from daily cocaine injections reverse established sensitization. Eur J Pharmacol 2002, 453:255-263.
9. Davidson C., Lee T.H., Xiong Z., Ellinwood E.H. Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. Neuropsychopharmacology 2002, 27:542-553.
10. Davidson C., Lee T.H., Ellinwood E.H. The NK(1) receptor antagonist WIN51708 reduces sensitization after chronic cocaine. Eur J Pharmacol 2004, 499:355-356.
11. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verriele L., Carpenter N., et al. Differential actions of anti-Parkinson's agents at multiple classes of monoaminergic receptor III agonist and antagonist properties at serotonin. J Pharmacol Exp Ther 2002, 303:815-822.
12. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis [Review]. Neuropsychopharmacology 2001, 24:29-97.
13. Guide for Care and Use of Laboratory Animals 1996, The National Academies Press, Washington, DC.
14. King G.R., Ellinwood E.H., Silvia C., Joyner C.M., Xue Z., Caron M.G., et al. Withdrawal from continuous or intermittent cocaine administration: changes in D2 receptor function. J Pharmacol Exp Ther 1994, 269:743-749.
15. Cho A.K., Melega W.P., Kuczensk R., Segal D.S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 2001, 39:161-166.
16. Ellinwood E.H., Balster R.L. Rating the behavioral effects of amphetamine. Eur J Pharmacol 1974, 28:35-41.
17. Lyon M., Randrup A. The dose-response effect of amphetamine upon avoidance behaviour in the rat seen as a function of increasing stereotypy. Psychopharmacologia 1972, 23:334-347.
18. Gawin F.H., Ellinwood E.H. Cocaine and other stimulants: actions, abuse and treatment. N Engl J Med 1988, 318:1173-1181.
19. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993, 18:247-291.
20. Mulvaney F.D., Alterman A.I., Boardman C.R., Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat 1999, 16:129-135.
21. Kampman K.M., Alterman A.I., Volpicelli V.R., Maany I., Muller E.S., Luce D.D., et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict 2001, 15:52-59.
22. Newton T.F., Kalechstein A.D., Tervo K.E., Ling W. Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. Addict Behav 2003, 28:817-821.
23. Sofuoglu M., Dudish-Poulsen S., Brown S.B., Hatsukami D.K. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003, 69:273-282.
24. Barros H.M., Miczek K.A. Withdrawal from oral cocaine in rate: ultrasonic vocalizations and tactile startle. Psychopharmacology 1996, 125:379-384.
25. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Ondansetron inhibits a behavioral consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 1990, 6:339-344.
26. Fung Y.K., Richard L.A. Behavioural consequences of cocaine withdrawal in rats. J Pharm Pharmacol 1994, 46:150-152.
27. Koeltzow T.E., White F.J. Behavioral depression during cocaine withdrawal is associated with decreased spontaneous activity of ventral tegmental area dopamine neurons. Behav Neurosci 2003, 117:860-865.
28. Zhou Y., Spangler R., Ho A., Kreek M.J. Increased CRH mRNA levels in the rat amygdale during short-term withdrawal from cocaine "binge" cocaine. Brain Res Mol Brain Res 2003, 114:73-79.
29. Davidson C., Gopalan R., Ahn C., Chen Q., Mannelli P., Patkar A.A., et al. Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. Eur J Pharmacol 2007, 565:113-118.
30. Grant K.A. The role of 5-HT3 receptors in drug dependence. Drug Alcohol Depend 1995, 38:155-171.
31. Barnes J.M., Costall B., Coughlan J., Domeney A.M., Gerrard P.A., Kelly M.E., et al. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 1990, 35:955-962.
32. Johnson B.A., Roache J.D., Ait-Daoud N., Javors M.A., Harrison J.M., Elkashef A., et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006, 84:256-263.
33. de Leeuw A.S., Westenberg H.G. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J Psychiatr Res 2008, 42:894-901.
34. Landén M., Thase M.E. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol Bull 2006, 39:147-166.
35. Kent J.M. SNaRIs NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000, 355:911-918.
36. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
37. Berretta S. Cortico-amygdala circuits: role in the conditioned stress response. Stress 2005, 8:221-232.
38. Jakab R.L., Goldman-Rakic P.S. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 2000, 417:337-348.
39. Nakayama K., Sakurai T., Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull 2004, 63:237-241.
40. Millan M.J., Gobert A., Rivet J.M., Adhumeau-Auclair A., Cussac D., Newman-Tancredi A., et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 2000, 12:1079-1095.
41. de Boer T.H., Maura G., Raiteri M., de Vos C.J., Wieringa J., Pinder R.M. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988, 27:399-408.
42. McDaid J., Tedford C.E., Mackie A.R., Dallimore J.E., Mickiewicz A.L., Shen F., et al. Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats. Drug Alcohol Depend 2007, 86:55-66.
43. Lanteri C., Salomon L., Torrens Y., Glowinski J., Tassin J.P. Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology 2008, 33:1724-1734.
44. Malcolm R., Kajdasz D.K., Herron J., Anton R.F., Brady K.T. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend 2000, 60:161-168.
45. Levin F.R., McDowell D., Evans S.M., Brooks D., Spano C., Nunes E.V. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am J Addict 1999, 8:120-127.
46. Haney M., Foltin R.W., Fischman M.W. Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (Berl) 1998, 137:15-24.
47. Nader K. Memory traces unbound. Trends Neurosci 2003, 26:65-72.
48. Centonze D., Siracusano A., Calabresi P., Bernardi G. Removing pathogenic memories: a neurobiology of psychotherapy. Mol Neurobiol 2005, 32:123-132.
49. Lee J.L., Everitt B.J., Thomas K.L. Independent cellular processes for hippocampal memory consolidation and reconsolidation. Science 2004, 304:839-843.
50. Lee J.L., Di Ciano P., Thomas K.L., Everitt B.J. Disrupting reconsolidation of drug memories reduces cocaine-seeking behavior. Neuron 2006, 47:795-801.
51. Schiller D., Monfils M.H., Raio C.M., Johnson D.C., Ledoux J.E., Phelps E.A. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2010, 463:49-53.